Skip to main content
. 2017 Oct 23;29(1):139–144. doi: 10.1093/annonc/mdx688

Figure 1.

Figure 1.

Efficacy outcomes stratified by tumor type for the efficacy-assessable population of patients with CpG island methylator phenotype (CIMP-high) colorectal cancer (CRC; n = 15) and patients with small bowel adenocarcinoma (SBA; n = 10). (A) Best radiographic response according to Response Evaluation Criteria in Solid Tumors (RECIST). (B) Progression-free survival curves for each cohort. (C) Overall survival curves for each cohort.